Events 2017 banner

ELRIG UK, today announced its 2017 events programme. The series of three events throughout the year has been designed to provide a platform for stimulation of discussions on a variety of topics of interest to researchers working in early drug discovery. All events feature a programme of world class science presentations from leaders in their fields, a trade show and exhibition, and poster competitions. Selected shows also have an innovation zone, aimed at showcasing the most exciting emerging life science companies. Delegate attendance at each of the events is free of charge.

Research & Innovation – Homerton College, Cambridge, 29-30 March 2017
Research & Innovation will bring together leading experts to discuss the challenges and opportunities for cells as models of disease to improve the success of drug discovery and develop new therapeutic agents.

Advances in Cell-Based Screening – AstraZeneca, Gothenburg, Sweden, 10-11 May 2017
This interactive event will host leading scientists from academia and industry to discuss the latest developments in cell based screening in drug discovery. The meeting has been developed to cover key topics such as advanced cell models, applied omics, assays/methods exploring mode of action, phenotypic screening, target deconvolution, and much more.

Drug Discovery 2017 – ACC, Liverpool, 3-4 October 2017
ELRIG UK’s flagship event, now in its 11th year, bring together leading lights in drug discovery research across pharma, biotech, academia and the vendor community to explore innovative technologies and approaches that can be used to overcome drug development challenges.

Steve Rees, Chairman, ELRIG UK, said: “ELRIG UK is widely recognised as one of the UK’s most respected life science organisations, and we are committed to ensuring that our events provide highly relevant content and networking opportunities. In 2016 we saw record numbers of delegates attending our events, and our aim for 2017 is to build on that success, making our meetings accessible to an even broader audience.”